4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Cellectis S.A. (CLLS) operates in the Biotechnology industry and is headquartered in Paris, France with about 224 employees. Its market capitalization is roughly $326 million. In the fiscal year ended 2025-12-31, CLLS reported $73M in revenue and ($68M) in net income.
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
Interactive charts & full statements → Open the CLLS valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $73M | $42M | $1M | $19M | — |
| Gross Profit | $63M | $32M | ($7M) | $11M | — |
| Operating Income (EBIT) | ($33M) | ($60M) | ($97M) | ($90M) | — |
| Net Income | ($68M) | ($37M) | ($101M) | ($106M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $5M | $6M | $10M | $35M | $17M | — |
| Gross Profit | $3M | $4M | $7M | $33M | $14M | — |
| Operating Income (EBIT) | ($24M) | ($25M) | ($17M) | $8M | ($10M) | — |
| Net Income | ($22M) | ($18M) | ($26M) | $1M | ($24M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | $0M | $0M | $0M | $0M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|
| Dividends Paid | $0M | $0M | $0M | $0M | $0M | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $325M | $384M | $334M | $261M | — |
| Total Liabilities | $249M | $252M | $250M | $135M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CLLS viewer.
About TickerBase · Data methodology & sources · Privacy · Terms